Should I buy or sell NeuroPace stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks .

What is NeuroPace's stock price target for 2024?

7 brokerages have issued 12-month target prices for NeuroPace's stock. Their NPCE share price targets range from $9.00 to $22.00. On average, they predict the company's share price to reach $15.67 in the next year. This suggests a possible upside of 13.9% from the stock's current price. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts .

How have NPCE shares performed in 2024?

NeuroPace's stock was trading at $10.31 on January 1st, 2024. Since then, NPCE shares have increased by 33.4% and is now trading at $13.75. View the best growth stocks for 2024 here .

Are investors shorting NeuroPace?

NeuroPace saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 85,900 shares, an increase of 178.0% from the March 15th total of 30,900 shares. Based on an average daily trading volume, of 98,900 shares, the short-interest ratio is presently 0.9 days. Approximately 0.7% of the shares of the company are sold short. View NeuroPace's Short Interest .

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NPCE earnings forecast .

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) posted its earnings results on Tuesday, March, 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.10. The business had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative trailing twelve-month return on equity of 153.76%.

What guidance has NeuroPace issued on next quarter's earnings?

NeuroPace issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $73.0 million-$77.0 million, compared to the consensus revenue estimate of $74.6 million.

When did NeuroPace IPO?

NeuroPace (NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NPCE

NeuroPace (NPCE) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free NPCE Stock Alerts

$13.75

-0.29 (-2.07%)

(As of 04/17/2024 ET)

Compare

Today's Range: $13.53
▼
$14.19
50-Day Range: $12.37
▼
$17.50
52-Week Range: $3.80
▼
$18.15

Volume: 32,234 shs
Average Volume: 107,021 shs
Market Capitalization: $361.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.67

Get NeuroPace alerts:

NeuroPace MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 13.9% Upside
$15.67 Price Target
Short Interest: Healthy
0.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.36
Based on 9 Articles This Week
Insider Trading: Selling Shares
$6.73 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.14) to ($1.15) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

431st out of 913 stocks

Surgical & Medical Instruments Industry

44th out of 89 stocks

3.4

Analyst's Opinion

Consensus Rating
NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
NeuroPace has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.73% of the float of NeuroPace has been sold short.
Short Interest Ratio / Days to Cover
NeuroPace has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NeuroPace has recently increased by 177.99%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
NeuroPace does not currently pay a dividend.
Dividend Growth
NeuroPace does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NPCE.

1.9

News and Social Media Coverage

News Sentiment
NeuroPace has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for NeuroPace this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for NPCE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,734,345.00 in company stock.
Percentage Held by Insiders
27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for NeuroPace are expected to decrease in the coming year, from ($1.14) to ($1.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NeuroPace is -10.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NeuroPace is -10.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NeuroPace has a P/B Ratio of 17.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About NeuroPace Stock (NASDAQ:NPCE)

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NPCE Stock News Headlines

April 16, 2024 | insidertrades.com

NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in Stock

April 17, 2024 | globenewswire.com

NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 16, 2024 | americanbankingnews.com

NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 Shares

April 15, 2024 | americanbankingnews.com

Head-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)

April 14, 2024 | americanbankingnews.com

NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

April 10, 2024 | fool.com

NeuroPace (NASDAQ: NPCE)

April 4, 2024 | msn.com

'Biggest mistake' bond investors may make ahead of Fed rate cuts

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 27, 2024 | globenewswire.com

NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

March 13, 2024 | markets.businessinsider.com

The Latest Analyst Ratings For NeuroPace

March 7, 2024 | markets.businessinsider.com

NeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers

March 7, 2024 | finance.yahoo.com

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

NeuroPace Full Year 2023 Earnings: EPS Beats Expectations

March 7, 2024 | seekingalpha.com

NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript

March 6, 2024 | benzinga.com

Recap: NeuroPace Q4 Earnings

March 6, 2024 | msn.com

NeuroPace GAAP EPS of -$0.23

March 6, 2024 | markets.businessinsider.com

NeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending Concerns

March 5, 2024 | globenewswire.com

NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million

March 5, 2024 | investorplace.com

Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio

February 24, 2024 | msn.com

NeuroPace (NPCE) Price Target Increased by 27.95% to 15.01

February 22, 2024 | benzinga.com

A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts

February 22, 2024 | benzinga.com

NeuroPace Stock (NASDAQ:NPCE) Earnings Dates and Earning Calls

February 15, 2024 | finance.yahoo.com

NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

February 15, 2024 | globenewswire.com

NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

February 8, 2024 | msn.com

NeuroPace Announces Chief Legal Officer Irina Ridley’s Departure

February 7, 2024 | uk.finance.yahoo.com

NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares

See More Headlines

Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NPCE
CUSIP: N/A
CIK: 1528287
Web: www.neuropace.com
Phone: 650-237-2700
Fax: N/A
Employees: 171
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.67
High Stock Price Target: $22.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +13.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,960,000.00
Net Margins: -50.38%
Pretax Margin: -50.38%
Return on Equity: -153.76%
Return on Assets: -31.73%

Debt

Debt-to-Equity Ratio: 2.76
Current Ratio: 5.71
Quick Ratio: 5.02

Sales & Book Value

Annual Sales: $65.42 million
Price / Sales: 5.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.79 per share
Price / Book: 17.41

Miscellaneous

Outstanding Shares: 26,280,000
Free Float: 19,056,000
Market Cap: $361.35 million
Optionable: Optionable
Beta: 2.08

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Martha J. Morrell (Age 67)
Chief Medical Officer
Comp: $555.87k
Mr. Joel D. Becker (Age 56)
CEO, President & Director
Ms. Rebecca L. Kuhn (Age 63)
CFO, VP of Finance & Administration and Assistant Secretary
Comp: $440.92k
Ms. Kelley Nicholas
Vice President of Sales
Ms. Irene Thomas (Age 55)
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NPCE Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings or view top-rated stocks.
What is NeuroPace's stock price target for 2024?: 7 brokerages have issued 12-month target prices for NeuroPace's stock. Their NPCE share price targets range from $9.00 to $22.00. On average, they predict the company's share price to reach $15.67 in the next year. This suggests a possible upside of 13.9% from the stock's current price.
View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts.
How have NPCE shares performed in 2024?: NeuroPace's stock was trading at $10.31 on January 1st, 2024. Since then, NPCE shares have increased by 33.4% and is now trading at $13.75.
View the best growth stocks for 2024 here.
Are investors shorting NeuroPace?: NeuroPace saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 85,900 shares, an increase of 178.0% from the March 15th total of 30,900 shares. Based on an average daily trading volume, of 98,900 shares, the short-interest ratio is presently 0.9 days. Approximately 0.7% of the shares of the company are sold short.
View NeuroPace's Short Interest.
When is NeuroPace's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NPCE earnings forecast.

How were NeuroPace's earnings last quarter?: NeuroPace, Inc. (NASDAQ:NPCE) posted its earnings results on Tuesday, March, 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.10. The business had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative trailing twelve-month return on equity of 153.76%.
What guidance has NeuroPace issued on next quarter's earnings?: NeuroPace issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $73.0 million-$77.0 million, compared to the consensus revenue estimate of $74.6 million.
When did NeuroPace IPO?: NeuroPace (NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.
How do I buy shares of NeuroPace?: Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NPCE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial